AFT Pharmaceuticals (AFT) reported an operating FY23 result in-line with guidance and slightly ahead of our expectations with EBIT ex licensing income of NZ$18.8m (FB; NZ$17.7m, guidance mid-point; NZ$19.3m) – up +38% versus FY22
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.